Gangliosides and the Guillain-Barre syndromeBMJ 1994; 308 doi: https://doi.org/10.1136/bmj.308.6944.1638a (Published 18 June 1994) Cite this as: BMJ 1994;308:1638
- G Landi,
- A Ciccone,
- R D'Alessandro,
- B C Dossi,
- S Ricci,
- I L Simone
- Ospedale Policlinico, 20122 Milan, Italy Policlinico S Orsola Bologna Ospedale degli Infermi Rimini Ospedale Policlinico Perugia Istituto di Clinica delle Malatti Nervose e Mentali, Universita di Bari.
EDITOR, - Various authors criticised our report on Guillain-Barre syndrome after gangliosides.1 Francesco Grigoletto computed the cases of the syndrome expected by chance alone according to age specific frequencies of therapeutic cycles of gangliosides.2 Without defining “therapeutic cycle” he concluded that our 24 cases were equal to the number expected by chance in Italy. However, to obtain this result he considered one month after gangliosides were given as the period at risk, whereas we considered only the first three weeks and excluded cases with later …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial